PMID- 24647104
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20140320
LR  - 20211021
IS  - 1999-4923 (Print)
IS  - 1999-4923 (Electronic)
IS  - 1999-4923 (Linking)
VI  - 6
IP  - 1
DP  - 2014 Mar 18
TI  - Application of pharmacokinetic and pharmacodynamic analysis to the development of 
      liposomal formulations for oncology.
PG  - 137-74
LID - 10.3390/pharmaceutics6010137 [doi]
AB  - Liposomal formulations of anticancer agents have been developed to prolong drug 
      circulating lifetime, enhance anti-tumor efficacy by increasing tumor drug 
      deposition, and reduce drug toxicity by avoiding critical normal tissues. Despite 
      the clinical approval of numerous liposome-based chemotherapeutics, challenges 
      remain in the development and clinical deployment of micro- and nano-particulate 
      formulations, as well as combining these novel agents with conventional drugs and 
      standard-of-care therapies. Factors requiring optimization include control of 
      drug biodistribution, release rates of the encapsulated drug, and uptake by 
      target cells. Quantitative mathematical modeling of formulation performance can 
      provide an important tool for understanding drug transport, uptake, and 
      disposition processes, as well as their role in therapeutic outcomes. This review 
      identifies several relevant pharmacokinetic/pharmacodynamic models that 
      incorporate key physical, biochemical, and physiological processes involved in 
      delivery of oncology drugs by liposomal formulations. They capture observed data, 
      lend insight into factors determining overall antitumor response, and in some 
      cases, predict conditions for optimizing chemotherapy combinations that include 
      nanoparticulate drug carriers.
FAU - Ait-Oudhia, Sihem
AU  - Ait-Oudhia S
AD  - Department of Pharmaceutical Sciences, University at Buffalo, State University of 
      New York, Amherst, NY 14214, USA. Sihema@buffalo.edu.
FAU - Mager, Donald E
AU  - Mager DE
AD  - Department of Pharmaceutical Sciences, University at Buffalo, State University of 
      New York, Amherst, NY 14214, USA. dmager@buffalo.edu.
FAU - Straubinger, Robert M
AU  - Straubinger RM
AD  - Department of Pharmaceutical Sciences, University at Buffalo, State University of 
      New York, Amherst, NY 14214, USA. rms@buffalo.edu.
LA  - eng
GR  - R21 CA168454/CA/NCI NIH HHS/United States
PT  - Journal Article
DEP - 20140318
PL  - Switzerland
TA  - Pharmaceutics
JT  - Pharmaceutics
JID - 101534003
PMC - PMC3978529
EDAT- 2014/03/22 06:00
MHDA- 2014/03/22 06:01
PMCR- 2014/03/01
CRDT- 2014/03/21 06:00
PHST- 2014/01/14 00:00 [received]
PHST- 2014/02/22 00:00 [revised]
PHST- 2014/02/26 00:00 [accepted]
PHST- 2014/03/21 06:00 [entrez]
PHST- 2014/03/22 06:00 [pubmed]
PHST- 2014/03/22 06:01 [medline]
PHST- 2014/03/01 00:00 [pmc-release]
AID - pharmaceutics6010137 [pii]
AID - pharmaceutics-06-00137 [pii]
AID - 10.3390/pharmaceutics6010137 [doi]
PST - epublish
SO  - Pharmaceutics. 2014 Mar 18;6(1):137-74. doi: 10.3390/pharmaceutics6010137.